Basic Information
bYoRNA SAS is a French biotechnology company focused on developing cost-effective and scalable mRNA bio-production platforms for preventive and cancer vaccines. Currently, mRNA is produced in vitro through enzymatic synthesis, which is an expensive method. Our bio-production technology will leverage processes within engineered living cells to enable the large-scale, cost-effective, and scalable production of long GMP-grade mRNA. By reducing the production costs of mRNA and streamlining the supply chain to make it localized and more resilient, bYoRNA will help deliver mRNA vaccines to populations in emerging countries. By generating longer, naturally modified mRNA, bYoRNA will facilitate the emergence of novel mRNA-based modalities.